Non-Small-Cell Lung Carcinoma (NSCLC)
A Non-Small-Cell Lung Carcinoma (NSCLC) is am epithelial lung cancer that is not a small-cell lung carcinoma (SCLC).
- See: Adjuvant Therapy, Micrograph, Squamous Carcinoma, FNA Specimen, Pap Stain, Lung Cancer, Small-Cell Lung Carcinoma, Chemotherapy, Neoadjuvant Therapy.
References
2022
- (Wikipedia, 2022) ⇒ https://en.wikipedia.org/wiki/Non-small-cell_lung_carcinoma Retrieved:2022-2-10.
- Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer other than small-cell lung carcinoma (SCLC). NSCLC accounts for about 85% of all lung cancers. As a class, NSCLCs are relatively insensitive to chemotherapy, compared to small-cell carcinoma. When possible, they are primarily treated by surgical resection with curative intent, although chemotherapy has been used increasingly both preoperatively (neoadjuvant chemotherapy) and postoperatively (adjuvant chemotherapy).
2021
- https://www.frontiersin.org/articles/10.3389/fonc.2021.672916/full
- QUOTE: ... In clinical trials that assess novel therapeutic agents in patients with non-small-cell lung cancer (NSCLC), overall survival (OS) is considered the gold-standard endpoint for establishing clinical benefit (1–3). ‘Early’ endpoints, such as progression-free survival (PFS) and objective response rate (ORR), ...
... Furthermore, high-quality real-world evidence (RWE) could be leveraged to enable drug approvals in oncology, linking it to the value proposition of drugs. Regulatory bodies, such as the US Food and Drug Administration, have recently shown a willingness to expedite access to new cancer medicines by using RWE ...
- QUOTE: ... In clinical trials that assess novel therapeutic agents in patients with non-small-cell lung cancer (NSCLC), overall survival (OS) is considered the gold-standard endpoint for establishing clinical benefit (1–3). ‘Early’ endpoints, such as progression-free survival (PFS) and objective response rate (ORR), ...